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Abstract
Background: Histone deacetylase 3 (HDAC3) belongs to a family of proteins which plays an important role in protein
acetylation, chromatin remodeling and transcription of genes, including those that are involved in cell proliferation and cell
death. While increased expression of HDAC3 is seen in neoplastic cells, the role of HDAC3 in T cells and their role in
autoimmune disease is not known.
Methodology/Principal Findings: Applying Affymetrix GeneChip Human Gene 1.0 ST Array and the mixed effects model for
gene set analysis, we compared gene expression profiles between multiple sclerosis (MS) patients and healthy controls (HC).
Within the Apoptosis_GO gene set, the constitutive expression level of HDAC3 in peripheral blood mononuclear cell (PBMC)
was significantly increased in MS patients when compared to controls. Following addition of trichostatin A (TSA), an
inhibitor of HDAC3, we examined the expression of p53 by flow cytometry and p53 targeted genes by real time RT-PCR in
MS and HC. Culture of PBMC with TSA resulted in increased expression of p53 in HC but not in MS patients. TSA treated T
cells from MS patients also showed reduced sensitivity to apoptosis when compared to HC, which was independent of
activation of p53 targeted pro-apoptotic genes.
Conclusion/Significance: MS patients, when compared to controls, show an increased expression of HDAC3 and relative
resistance to TSA induced apoptosis in T cells. Increased expression of HDAC3 in PBMC of MS patients may render putative
autoreactive lymphocytes resistance to apoptosis and thereby contribute to autoimmunity.
Citation: Zhang F, Shi Y, Wang L, Sriram S (2011) Role of HDAC3 on p53 Expression and Apoptosis in T Cells of Patients with Multiple Sclerosis. PLoS ONE 6(2):
e16795. doi:10.1371/journal.pone.0016795
Editor: Sue Cotterill, St. Georges University of London, United Kingdom
Received August 10, 2010; Accepted January 14, 2011; Published February 8, 2011
Copyright:  2011 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: National Multiple Sclerosis Society. The funding agency had no role in the study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Subramaniam.sriram@vanderbilt.edu
Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS) and is the most
common neurological disease of the CNS affecting young adults
[1]. Although the etiology of the disease is not known, the
consensus of opinion is that MS is an autoimmune disease that is
initiated by exposure to an environmental agent, most likely a
pathogen, in genetically susceptible individuals [1,2,3,4]. Expan-
sion of autoreactive cells to putative neural antigens is thought to
play a role in MS [5,6]. Although a number of genes have been
implicated in the development of MS, there are as yet no genes or
gene sets that have been identified to be specific for MS.
One of the key events that regulate gene activation involves the
architectural organization of the nucleosome that is mediated by
the state of acetylation and deacetylation of lysine residues in the
amino terminal tail of histones. Histone deacetylase (HDAC) leads
to condensation of nucleosome, while histone acetyl transferase
(HAT), leads to hyperacetylation and relaxation of the nucleosome
thereby permitting the binding of transcription factors to the DNA
thus allowing gene transcription [7,8,9,10]. Acetylation and
deacetylation of histone proteins play a pivotal role in the
epigenetic regulation in many cell types, including immune
lymphocytes. In addition to histones, HAT and HDAC use a
number of non-histone proteins as substrates, including p53, NF-
kb and STAT [11,12,13]. These protein substrates are involved in
the regulation of cellular immunity and cell proliferation.
Advances in the understanding of HDAC and HAT have provided
new insights into the regulation of proteins that are involved in cell
cycle progression, transcription and cell death [14,15,16].
HDACs are evolutionarily conserved proteins and are widely
expressed. To date, at least 11 isoforms of HDAC are known in
human but the functions of the different individual HDAC
isoforms in regulating cell proliferation and cell death is not fully
established. The different isoforms of HDAC are broadly grouped
into four classes, based on their homology to yeast genes. Class I
HDAC’s (1,2,3 and 8) share homology with the yeast transcrip-
tional regulator RPD3, class II HDAC (HDAC 4–7, 9–11) have
similarity to yeast Hda1 gene and class III (SIRTs 1–7) share
homology with NAD family of sirtuin proteins [9,17]. HDAC3
contains an unusual C terminus and, unlike the predominantly
nuclear HDAC1 and HDAC2, localizes to the nucleus, cytoplasm,
and plasma membrane, indicating that HDAC3 is functionally
distinct from other members of its class [9].
In some neoplastic diseases, expression and activation of p53 is
regulated by HDAC [10,18,19]. P53 is a key transcription
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and cell cycle arrest [20,21,22]. In the cytosol p53 binds to mdm2
and is rapidly degraded. Hence, the half life of p53 is short (less
than 30 minutes) and constitutive expression of p53 is barely
detectable in lymphocytes using conventional western blotting
method. Acetylation of lysine residues on p53 abrogates the
complex formation between p53 and mdm2, which will lead to an
increase in the half life of p53 [12,16]. Given that autoimmune
disease represents unchecked expansion of autoreactive cells, we
proposed that HDAC could regulate the expression and function
of p53, and thereby affect the function of T cells, a key player in
autoimmunity. We examined the constitutive expression of
HDAC3 in peripheral blood mononuclear cell (PBMC) of patients
with MS and compared them with HC. We also examined the
effect of TSA, a known HDAC inhibitor, on the expression and
apoptotic function of p53 in T cells of MS patients and HC.
Results
Microarray analysis of expression of the apoptosis gene
sets between MS patients and healthy controls
We used a unified mixed effects model for gene set analysis to
screen 825 gene sets corresponding to the biological process
categories from the Gene Ontology project [23]. Using this mixed
model gene set analysis and by combining weak signals of
differential expression across genes within the same gene set, we
identified gene sets that were differentially expressed between MS
and healthy controls in unstimulated PBMC. Table 1 shows that 8
out of 825 gene sets whose function related to cell death were
down-regulated in MS patients. We examined the genes in the
Apoptosis_GO gene set which differentiated MS from HC at a
statistically significant level (Table 2 and Figure 1a). Of the 38
differentially expressed genes in the Apoptosis_GO gene set,
HDAC3 was expressed at levels that were significantly higher in
MS patients when compared to HC (p=0.001). To confirm our
observation from our micro-array studies, we quantitated the
mRNA levels of HDAC3 in MS patients (n=12) and controls
(n=12) using real time RT-PCR. As shown in Figure 1b, the
expression of HDAC3 normalized to beta actin was higher in MS
patients when compared to controls (p=0.002).
Activation of p53 by TSA in PBMC – dose and time
kinetics in healthy controls
Since HDACs are known to play a role in the expression of pro-
apoptotic proteins including p53, we examined the expression of
p53, under conditions that decreased HDAC3 expression. We
predicted that trichostatin A (TSA), which inhibits HDAC, will
increase expression of p53 in T lymphocytes. PBMC (1610
6 cells/
ml) were cultured in vitro for 48h in the presence or absence of
TSA, and the amount of p53 was determined by flow cytometry.
We chose to use flow cytometry than conventional western
blotting, since the former appeared to be more sensitive in
detecting small differences in the cellular expression of p53. As
shown in figure 2a and 2b, a dose and time dependant increase in
p53 expression was seen following addition of TSA. P53
expression as determined by flow cytometry was maximal at a
TSA concentration of 0.5 mM. After a 2 day culture, increased
expression of p53 expression was seen in CD3+, CD3+/CD4+ and
CD3+/CD8+ subsets of T lymphocytes (Figure 2c).
Induction of apoptosis in PBMC cells cultured with TSA
We next examined if increased expression of p53 in T
lymphocytes in the presence of TSA leads to increase in apoptosis.
As shown in figure 3a, there was dose dependant increase in the
number of Annexin V+ cells and Annexin V+/7-AAD+ cells
following the culture of PBMC with TSA. The number of viable
PBMC decreased from 85.4% in the absence of TSA to 54.8%
following a 2 day culture with 1 mM of TSA. Kinetic study
performed with 0.5 mM of TSA showed that the number of viable
cells, decreased from 85.4% at 0 h to 60.7% at 48 h (Figure 3a).
Subset analysis of PBMC showed that the decrease in cell viability
involved both CD3+/CD4+ and CD3+/CD8+ cells (Figure 3b).
Induction of p53 in PBMC of MS patients and healthy
controls
Since MS patients showed an increase in the constitutive levels
of HDAC3, we predicted that PBMC from MS patients will be
more resistant to the inhibitory actions of TSA on HDAC and will
be reflected in reduced levels of p53 in MS patients when
compared to HC. In 6 MS patients and an equal number of HC,
the expression of p53 in T lymphocytes cultured with TSA was
examined. As shown in figure 4a, induction of p53 following
culture of PBMC with TSA was seen in all 6 healthy controls. In
contrast, we did not observe an increase in the expression of p53,
following culture with TSA in any of the 6 MS patients (Figure 4).
TSA mediated apoptosis is decreased in MS patients
when compared to controls
Since PBMC of MS patients cultured with TSA failed to show
an increase in cellular expression of p53, we predicted that PBMC
of MS patients will be less susceptible to TSA induced apoptosis
when compared to healthy controls. Apoptosis to TSA was
examined in 18 MS patients and 12 HC and is shown in Figure 5.
Table 1. Differentially expressed gene sets involved in apoptosis biological process in MS patients compared to healthy controls.
GO term Gene set name Size Raw_p FDR_p
GO:0006915 APOPTOSIS_GO 424 0.0038 0.0689
GO:0012501 PROGRAMMED_CELL_DEATH 425 0.0041 0.0703
GO:0042981 REGULATION_OF_APOPTOSIS 335 0.0069 0.0961
GO:0043067 REGULATION_OF_PROGRAMMED_CELL_DEATH 336 0.0076 0.1023
GO:0006281 DNA_REPAIR 121 0.0322 0.2742
GO:0008624 INDUCTION_OF_APOPTOSIS_BY_EXTRACELLULAR_SIGNALS 27 0.0337 0.2833
GO:0006974 RESPONSE_TO_DNA_DAMAGE_STIMULUS 156 0.0425 0.3297
Mixed Models Analysis of the gene sets based on biological process categories from the Gene Ontology project. Size = number of genes in the gene set; Raw_p =
nominal p-value; FDR_p = FDR adjusted p-value.
doi:10.1371/journal.pone.0016795.t001
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cells, MS patients showed reduced susceptibility to TSA mediated
apoptosis (p,0.05 HC vs. MS). Since the MS population included
some patients who were on immunomodulatory therapy, we
examined if sensitivity to apoptosis was different between MS
patients who were untreated (7) when compared to those on either
beta interferon(5), glatiramer acetate (3), methotrexate (2), or
mycophenalate (1). There was no significant difference between
treated and untreated patients in the response of PBMC to
apoptosis following culture with TSA, which may be due to the
small number of patients in each treatment group (data not
shown).
Activation of p53 targeted genes in TSA treated PBMC in
MS and HC
To evaluate if the increased expression of p53 and the attendant
increase in apoptosis seen in TSA treated PBMC was due to the
transcriptional regulation of p53 regulated pro-apoptotic genes, we
examined the expression of the following genes by real time RT-
PCR: (i) p21, (ii) Bax, (iii) Noxa, (iv) Puma and (v) mdm2. As
Table 2. Genes within the apoptosis gene set that were differentially expressed between MS patients and controls.
Gene
GenBank accession
number
Direction of changed
regulation P-value Description
HDAC3 NM_003883 up 0.0011 Histone deacetylase 3
NFKB1 NM_003998 up 0.0063 Nuclear factor NF-kappa-B p105 subunit
CCL2 NM_002982 up 0.0063 C-C motif chemokine 2 Precursor
IL1B NM_000576 up 0.0069 Interleukin-1 beta Precursor
HTATIP2 NM_001098520 up 0.0070 Oxidoreductase HTATIP2
NLRC4 NM_021209 up 0.0073 NLR family CARD domain-containing protein 4
PHB NM_002634 up 0.0116 Prohibitin
ACVR1B NM_004302 up 0.0133 Activin receptor type-1B Precursor
NLRP1 NM_001033053 down 0.0135 NACHT, LRR and PYD domains-containing protein 1
PSEN1 NM_000021 up 0.0137 Presenilin-1
TXNL1 NM_004786 up 0.0138 Thioredoxin-like protein 1
CASP2 NM_032982 down 0.0161 Caspase-2 Precursor
P53AIP1 NM_022112 down 0.0165 tumor protein p53 regulated apoptosis inducing protein 1
BID NM_001196 up 0.0195 BH3-interacting domain death agonist
IL1A NM_000575 up 0.0200 Interleukin-1 alpha Precursor
NFKBIA NM_020529 up 0.0213 NF-kappa-B inhibitor alpha
BECN1 NM_003766 up 0.0218 Beclin-1
PEA15 NM_003768 up 0.0241 Astrocytic phosphoprotein PEA-15
PSEN2 NM_000447 up 0.0244 Presenilin-2
RIPK1 NM_003804 up 0.0244 Receptor-interacting serine/threonine-protein kinase 1
TRAF3 NM_003300 up 0.0248 TNF receptor-associated factor 3
ANXA4 NM_001153 up 0.0276 Annexin A4
CBX4 NM_003655 down 0.0282 E3 SUMO-protein ligase CBX4
FOXO1 NM_002015 down 0.0294 Forkhead box protein O1
SON NM_032195 down 0.0298 SON protein
PROC NM_000312 down 0.0304 Vitamin K-dependent protein C Precursor
RAF1 NM_002880 up 0.0307 RAF proto-oncogene serine/threonine-protein kinase
DNM1L NM_005690 up 0.0309 Dynamin-1-like protein
BRE NM_004899 up 0.0313 Protein BRE
KIAA1967 NM_021174 up 0.0325 Protein KIAA1967
PDCD7 NM_005707 down 0.0333 Programmed cell death protein 7
BCL2L1 NM_001191 up 0.0380 Apoptosis regulator Bcl-X
DEDD2 NM_133328 up 0.0419 DNA-binding death effector domain-containing protein 2
TAX1BP1 NM_001079864 up 0.0433 Tax1-binding protein 1
TP53BP2 NM_001031685 up 0.0462 Apoptosis-stimulating of p53 protein 2
DEDD NM_001039711 up 0.0476 Death effector domain-containing protein
IL7 NM_000880 up 0.0480 Interleukin-7 Precursor
ASNS NM_001673 up 0.0493 Asparagine synthetase [glutamine-hydrolyzing]
Direction of changed regulation = the constitutive expression level of genes in PBMC from MS patients compared to that of healthy control.
doi:10.1371/journal.pone.0016795.t002
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expression of all the examined genes in TSA treated PBMC
(p,0.05 for all the five genes), there was no significant difference
in the induction for these genes between MS and HC.
Discussion
Our study shows that MS patients, when compared to controls,
have an increased expression of HDAC3 and reduced suscepti-
bility to TSA induced apoptosis in T lymphocytes, which was
associated with a lack of an increase in p53 expression in MS. Our
initial analysis based on the mixed effects model showed among 8
apoptosis related gene sets, Apoptosis_GO was the most significant
gene set, differentiating MS from HC. Although there were 424
genes in the Apoptosis_GO gene set, we focused our study on
HDAC3 since it showed the greatest difference in expression
between MS and HC. While there have been a number of studies
that have examined the expression pattern of genes in MS patients
and compared it with HC, an increase in HDAC3 has not been
previously reported [24,25,26]. Our study suggests that increased
expression of HDAC3 in PBMC of MS patients might represent a
new and as yet unrecognized biomarker for MS.
Since acetylation of histone and non histone proteins plays a key
role in epigenetic regulation, we examined the effect of HDAC
inhibition on key cellular function that is regulated by HDAC.
TSA is a well known inhibitor of HDACs and maintains the
sustained acetylation of proteins [10,14,27,28]. The mechanism by
which TSA induces cell death is not fully known, although studies
in tumor cell lines have suggested increase in the expression of
proteins involved in the DNA damage pathway, including the
activation of p53 which may influence cell survival [29,30].
Abnormalities in the regulation of HDAC3 expression have
been associated with tumorigenesis. Over expression of HDAC3
has been seen in colon cancer cell lines [31,32], and strong
expression of HDAC3 correlates with a poor prognosis in patients
with adenocarcinoma of the lung [33]. In acute lymphoblastic
Figure 1. Constitutive expression levels of HDAC3 in HC and MS patients. 1a. Heat map shows constitutive expression level of genes
involved in Apoptosis_GO gene set in MS patients and HC. The rows correspond to normalized, log (base 2) transformed gene expressions from
PBMC of 4 HC and 8 MS patients. Red color indicates high expression and blue color indicates low expression. 1b. Real Time RT-PCR verified that the
constitutive expression of HDAC3 in PBMC were significantly different (p=0.002) in HC and MS patients. In these box plots, the bottom, middle and
top of the box represent 25
th,5 0
th and 75
th percentile of gene expression levels normalized to beta actin in PBMC from 12 HC and 12 MS patients.
doi:10.1371/journal.pone.0016795.g001
Figure 2. p53 expression in PBMC following culture with TSA in HC examined by flow cytometry. 2a. The expression of p53 following
culture with TSA for 48 hrs at doses of 0.25 mM (top panel, blue line), 0.5 mM (middle panel, green line), 1.0 mM (bottom panel, red line). In all these
three panels, the dotted line represents isotype antibody control, and the purple line represents the expression of p53 in lymphocytes cultured with
DMSO in the absence of TSA. 2b. Increased expression of p53 following culture with 0.5 mM TSA at 6 h (top panel, blue line), 24 h (middle panel,
green line) and 48 h (bottom panel, red line) respectively. In all these three panels, the dotted line represents isotype antibody control, and the black
line represents expression of p53 in cells cultured with DMSO only. 2c. Expression of p53 in T cell subsets cultured with 0.5 mM of TSA for 48 h. Panels
from top to bottom are: PBMC, CD3+, CD4+/CD3+ and CD8+/CD3+ subset of T lymphocytes. In all these four panels, the dotted line represents
isotype antibody control; the red line represents the expression of p53 in cells cultured with DMSO in the absence of TSA and the blue line represents
the expression of p53 in lymphocytes cultured with 0.5 mM of TSA for 48 h. The x axis represents increasing fluorescence intensity of p53, y axis
represents cell number. Data are representative of 6 independent experiments.
doi:10.1371/journal.pone.0016795.g002
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HDAC3 were associated with a significantly lower 5-year event-
free survival [34]. For these reasons, HDAC inhibitors are
emerging as a new class of anticancer agent [18,19,32,35]. These
independent observations in tumor cells underscore the fact that
over expression of HDAC3 can lead to cellular effects that affect
cell growth, proliferation and the expression signaling proteins that
regulate the function of key cytokines involved in innate immunity.
At present factors that mediate the expression and activation of
HDACs including HADAC3 remain speculative. The increased
expression of HDAC2 in colorectal tumors is thought to be
mediated by the activation of Wnt/beta-catenin pathway
presumably through the activation of c-Myc [36]. In experimental
inflammatory conditions such as systemic sepsis, glucocorticoids
inhibit the expression of HDAC6 and HDAC3 [37]. It is not clear
if in inflammatory immune disorders, expression of HDAC is
influenced by pro and anti inflammatory molecules.
When compared to studies in cancer, expression of HDAC3
and its role in autoimmune disease has received limited attention.
Synovial fibroblasts from patient with rheumatoid arthritis have
shown increased expression of HDAC1 when compared to those
with osteoarthritis. Inhibition of HDAC1 resulted in increased
expression of pro-apoptotic proteins, including p53 and reduced
proliferation of synoviocytes [38]. In experimental allergic
encephalitis (EAE), a mouse model of MS, treatment of mice
with TSA improved clinical scores of paralysis [39]. Improvement
Figure 3. Detection of apoptosis by TSA in HC using flow cytometry. 3a. Top panel shows the increase in apoptosis in the presence of TSA at
concentration of 0 mM, 1 mM, 0.25 mM, 0.5 mM and 1 mM after 48 h culture. Bottom panel shows the kinetic of apoptosis in PBMC treated with TSA at
concentration of 0.5 mM for 6 h, 24 h and 48 h. 3b. Top panel shows apoptosis in DMSO treated cells as control. Bottom panel shows apoptosis in
0.5 mM TSA treated cells for 48 h. Both panels, from left to right, represent PBMC, CD3+, CD4+/CD3+ and CD8+/CD3+ lymphocytes respectively. Data
are the representative of 15 independent experiments.
doi:10.1371/journal.pone.0016795.g003
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of Th1 encephalitogenic cells. In addition, TSA was shown to up-
regulate anti–excitotoxicity and pro-neuronal growth and differ-
entiation factors, resulting in improved neurological outcomes in
mice with EAE [39]. While a general propensity for autoimmune
syndromes in individuals over-expressing HDAC in immune cells
may be anticipated, the factors underlying the development of
organ specific autoimmunity is unknown.
The tumor suppressor protein p53 is a highly regulated
transcription factor and is fundamental to the development of
tumors. The major function of p53 resides in its ability to act as an
important transcription factor of genes such as p21, Bax, Noxa,
Puma and mdm2 which are involved in cell proliferation and
death. It is now clear that in addition to its function as a
transcription factor of pro-apoptotic genes, post translational
modifications of p53 also plays a direct role in mitochondrial
mediated apoptosis [40,41]. The post translational modifications
of p53 include acetylation, methylation, sumoylation and ubiqui-
tination [42]. HDACs are known to regulate acetylation of p53 at
residues Lys-320/Lys- 373/Lys-382or Lys-120 [43,44]. The
acetylation of p53 leads to the decreased degradation, thereby
increases the constitutive level of the protein [12,16]. Acetylated
p53 can also directly translocate to the mitochondria, inhibiting
anti apoptotic proteins BCL-1 and BCL-XL leading to its
permeabilization and ultimate cell death [44,45,46].
Contrary to our expectation, the lack of an increase in p53 in
PBMC of MS patients when compared to HC in the presence of
TSA, was not associated with a parallel decrease in the
transcription of p53 upregulated apoptotic genes. Induction of
p21, Bax, Puma, Noxa and mdm2 by TSA were similar in MS
to those in HC. Hence, the reduced sensitivity to the apoptosis
of T lymphocytes treated with TSA in MS patients is unlikely to
be due to decreased induction of p53 regulated pro-apoptotic
genes. Acetylated p53 is more stable in T lymphocytes and we
also speculate that the increase in acetylated p53 by TSA may
lead to transcription-independent mitochondrial directed apop-
tosis, in a manner similar to the observations in tumor cell lines
[44,45,46].
Our study suggests that increased constitutive expression of
HDAC3 is associated with reduced apoptotic T lymphocytes in
MS patients. While our study has focused mainly on T cells, the
role of HDAC in other immune cells, including B cells,
macrophages and NK cells needs to be addressed. Tumor cells
appear to be sensitive to the inhibitory actions of TSA on
HDAC. A number of selective and non selective HDAC
inhibitors have been developed in the hope that decrease in
HDAC activity would lead to activation of key proteins involved
in regulation of cell proliferation and cell death [11,47,48,49]. It
is conceivable that HDAC inhibitors could also become part of
the therapeutic strategy in the treatment of immune disorders
including MS.
Materials and Methods
Subjects
34 patients with clinically definite MS (Table 3) and 33 healthy
volunteers were recruited from the MS clinic of Vanderbilt
Medical Center. The clinical subtypes of these MS patients were as
follows: (a) 26 relapsing remitting MS (RRMS), (b) 5 secondary
progressive MS (SPMS) and (c) 3 primary progressive MS (PPMS).
Of the 26 RRMS, 14 were receiving beta IFN, 4 were on
glatiramer acetate and 8 were on no therapy. Of the 8 patients
with progressive MS, 5 were on no therapy, 2 had received
methotrexate and 1 was on mycophenalate. The studies were
approved by the Committee for the Protection of Human Subjects
of the Vanderbilt University Institutional Review Board and the
written consent forms were obtained from all participants involved
in the study.
Figure 5. Susceptibility of PBMC to TSA induced apoptosis in HC and MS patients. Reduced susceptibility to TSA induced apoptosis in 18
MS patients when compared to 15 HC. PBMC were treated with 0.5 mM TSA for 48 h. Cells treated with DMSO in the absence of TSA served as a
negative control.
doi:10.1371/journal.pone.0016795.g005
Figure 4. Detection of p53 expression in PBMC treated with TSA in HC and MS patients using flow cytometry. Increased expression of
p53 in PBMC from HC but not in MS patients, treated with 0.5 mM TSA for 48 h. Dotted black line represents isotype antibody control; dotted green
line, represents p53 expression in the absence of TSA; red line, p53 expression in the presence of TSA. Results are shown as paired samples of MS
patients and HC; each pair was analyzed using flow cytometry on the same day.
doi:10.1371/journal.pone.0016795.g004
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Antibodies: anti-CD4-FITC, CD4-Pacific blue, CD8-APC,
CD3-PE and CD3-Pacific blue (BD Biosciences Pharmingen,
San Jose, CA); anti p53-PE (Santa Cruz Biotechnology, Santa
Cruz, CA).
Chemicals: Trichostatin A (TSA), dimethylsulfoxide (DMSO)
and Ficoll-Hypaque (Sigma-Aldrich, St. Louis, MO).
The following kits were used: Annexin V-FITC & 7-AAD
apoptosis detection kit (BD Biosciences Pharmingen, San Jose,
CA); Fixation and permeabilization kit (Invitrogen, Carlsbad, CA);
RNA isolation kit and RNase-free DNase set (Qiagen, Valencia,
CA); Reverse Transcription kit (Applied Biosystems, Foster City,
CA); iQ SYBR green supermix (Bio-Rad Laboratories, Hercules,
CA); Agilent’s Bioanalyzer microfluidic assay kit (Agilent Tech-
nologies, Palo Alto CA).
Isolation and culture of PBMC
Peripheral blood mononuclear cells (PBMC) were isolated by
density gradient centrifugation with Ficoll-Hypaque from freshly
heparinized blood. The cells were washed in PBS and re-
suspended at 1610
6 cells/ml in complete medium RPMI-1640
containing 2 mmol glutamine, 100 U/ml penicillin, 100 mg/ml
streptomycin and 10% fetal bovine serum (Invitrogen, Carlsbad,
CA). PBMC were cultured in the presence of TSA with the
different concentration and time points as indicated in the results
and figure legends.
Total RNA extraction and reverse transcription
Total RNA was extracted from PBMC by RNeasy mini kit and
treated with RNase-free DNase set, following manufacturer’s
recommendation. Agilent’s Bioanalyzer microfluidic assay was
applied to test RNA integrity. Spectrophotometric and fluoromet-
ric methods were combined to quantitate RNA. cDNA was
generated from RNA using Reverse Transcription kit. 1 mg of total
RNA was reverse transcribed in a total volume of 25 ml using 100
units of reverse transcriptase, 2.5 ml1 0 X RT buffer, 2.5 ml 10X
random primer and 1.5 mlo f2 0 U / ml RNase inhibitor. The
mixture was incubated for 10 min at 25uC, 120 min at 37uC, 5
seconds at 85uC and rapid cooling on ice. The cDNA samples
were stored at –20uC.
Real-time quantitative RT- PCR
Real-time quantitative RT-PCR reaction was carried out in an
iCycler detection system in a 25 ul volume. The reaction mixture
consisted of 12.5 ul iQSYBR Green Supermix, 200 nM of each
primer, and 1 ul of cDNA template. Reactions were performed for
45 cycles (95uC for 15 s, 60uC for 30 s and 72uC for 30 s) after an
initial 3 min incubation at 95uC. HDAC3 primers: 59gctggagg-
gaaaaggagtgg 39and 59 ggccttgggagagagaggaa 39. Other primers
for the target genes amplified are shown in the reference [50]. All
reactions were done in triplicates. Values for each gene were
normalized by those of internal control beta-actin using the Ct
Table 3. Demographics of the patients with multiple
sclerosis.
MS subtype gender age
1P P F 3 8
2R R M 3 6
3R R F 5 3
4R R M 2 7
5R R F 3 5
6R R F 5 7
7R R F 3 5
8R R F 3 6
9R R F 4 5
10 RR M 60
11 RR F 49
12 RR F 37
13 RR M 55
14 RR F 60
15 RR F 49
16 SP M 63
17 RR F 44
18 SP F 59
19 RR F 57
20 PP F 59
21 SP F 21
22 RR F 37
23 RR F 38
24 RR F 33
25 RR F 54
26 RR F 27
27 SP M 55
28 PP M 48
29 RR F 42
30 SP F 50
31 RR M 51
32 RR M 53
33 RR F 55
34 RR F 54
PP=progressive-relapsing multiple sclerosis; RR=relapsing-remitting multiple
sclerosis; SP=secondary-progressive multiple sclerosis. F=female;M=male.
doi:10.1371/journal.pone.0016795.t003
Figure 6. Real time RT-PCR studies on a panel of p53 regulated
genes in PBMC treated with TSA between HC and MS. PBMC
were treated with 0.5 mM TSA for 24 h, with DMSO in the absence of
TSA as control. Results are expressed as fold change in expression of
mRNA levels for each gene normalized to beta actin and compared to
control.
doi:10.1371/journal.pone.0016795.g006
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controls were calculated.
Microarray analysis
Microarray experiments were carried out as described previ-
ously [50]. Briefly, a total of 100 ng of total RNA was reverse
transcribed to cDNA which was then used as template in an in-
vitro transcription reaction followed by fragmentation of the single
stranded cDNA and labeling through a terminal deoxy-transferase
reaction. The biotinylated cDNA (5 mg) was fragmented and
hybridized to an Affymetrix GeneChip Human Gene 1.0 ST
Array with 764,885 probes representing 28,869 genes. GeneChips
were then scanned using GeneChip Scanner 3000 7G Plus 2 and
Command Console Software (AGCC) version 1.0 (Affymetrix Inc,
Santa Clara, CA). Raw gene expression data in the generated CEL
files were then normalized using the Robust MultiChip Averaging
(RMA) algorithm [51] as implemented in Bioconductor [52]. To
identify groups of functionally related genes that were differentially
expressed, we conducted gene set analysis using the mixed effects
models approach [23,53]. The C5-BP collection of gene sets from
http://www.broad.mit.edu/gsea/msigdb/index.jsp, which were
derived from the controlled vocabulary of the Gene Ontology
(GO) project, was used for these analyses. For each gene set, the
mixed model included gene expression levels as the outcome
variable, group (patients or healthy controls) as the fixed effects
and different batches, patients as the random effects. In addition,
random effects based on eigenvectors of the gene-gene correlation
matrix were included to account for heterogeneous correlation
patterns of the genes within a gene set [53]. Because many gene
sets were examined, to control the rate of false positive findings by
chance, we adjusted nominal p-values using the method of false
discovery rate [54]. All microarray data is MIAME compliant and
the raw data have been deposited in Gene Expression Omnibus
(GEO) database, with the accession number GSE23832.
Flow cytometry
PBMC were collected and incubated with CD4-FITC, CD8-
APC and CD3-Pacific blue for 30 min on ice. After washing, the
cells were fixed and permeabilized with AB reagents according to
manufacturer’s recommendation. PBMC were stained with p53-
PE 30 min in the dark and analyzed on BD LSRII flow cytometer.
To detect apoptosis, lymphocytes were collected and stained
with the Annexin V-FITC&7-AAD, as well as CD4-Pacific blue,
CD8-APC and CD3-PE and signals were detected in BD LSRII
flow cytometer. Data were analyzed by BD FACSDiva software
and apoptosis was determined by the positive staining of annexin
V and expressed as the increase in percentage of apoptotic cells in
TSA treated samples when compared to cells treated with DMSO.
Statistic analysis and software implementation
For the gene set analysis of microarray experiments, we used
Procedure MIXED within the SAS software (version 8.1; SAS
Institute, Cary, NC, USA) for fitting mixed effects models
described in the section Microarray Analysis. Other results from
real-time RT-PCR and flow cytometry were expressed as mean 6
SD, and statistical comparisons between the groups were
determined by T test using SPSS11.0 software and the R software
(http://www.R-project.org).
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